Skip to main content
. 2017 Jan 18;9(2):80–90. doi: 10.4254/wjh.v9.i2.80

Figure 1.

Figure 1

Serial computed tomography scans of a hepatocellular carcinoma patient with multiple co-morbidities precluding radical treatment, surviving 7 years with sequential approach in systemic treatment (Octreotide long acting release, followed by sorafenib). Despite an increase in tumor size, it is evident the central necrosis related to Sorafenib treatment (which was commenced when it became available).